Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Oct 7, 2022
Date Accepted: Jan 25, 2023

The final, peer-reviewed published version of this preprint can be found here:

The Effect of a mHealth App (KENPO-app) for Specific Health Guidance on Weight Changes in Adults With Obesity and Hypertension: Pilot Randomized Controlled Trial

Sakane N, Suganuma A, Domichi M, Sukino S, Abe K, Fujisaki A, Kanazawa A, Sugimoto M

The Effect of a mHealth App (KENPO-app) for Specific Health Guidance on Weight Changes in Adults With Obesity and Hypertension: Pilot Randomized Controlled Trial

JMIR Mhealth Uhealth 2023;11:e43236

DOI: 10.2196/43236

PMID: 37043287

PMCID: 10134028

Effect of the mHealth app (KENPO-app) for specific health guidance on weight changes in adults with obesity and hypertension: A pilot randomized controlled trial

  • Naoki Sakane; 
  • Akiko Suganuma; 
  • Masayuki Domichi; 
  • Sin Sukino; 
  • Keiko Abe; 
  • Akiyoshi Fujisaki; 
  • Ai Kanazawa; 
  • Mamiko Sugimoto

ABSTRACT

Background:

In 2008, all health insurers in Japan were mandated to provide specific health guidance (SHG) to prevent metabolic syndrome (MetS), type 2 diabetes (T2D), and cardiovascular diseases in middle-aged adults in Japan. In addition, the efficacy of SHG was small, and repeater eligibility for SHG was a problematic issue. The evaluation of outcome (i.e., ≥2 kg of weight loss) will be performed, and a mobile healthcare app will be introduced to the SHG. Commercial smartphone apps that promote self-monitoring of weight loss are widely available. The development of disease-specific apps has begun, but there is no app for SHG. Therefore, we developed the SHG-specific mHealth app (KENPO-app), and this study aimed to determine its efficacy in facilitating weight loss in Japanese adults with obesity and hypertension.

Objective:

This study aimed to determine the efficacy of specific health guidance (SHG) mHealth app in facilitating weight loss in Japanese adults with obesity.

Methods:

In a 12-week, statistician-blinded, randomized controlled trial, 78 overweight and obese men aged 40–69 years were assigned in a 1:1 ratio to either the usual support plus KENPO-app group (intervention group) or the usual support group (active control group). The KENPO app had chatbot-support feedback and information provision combined with a self-monitoring tool (weight, steps, and blood pressure).

Results:

The trial retention was 94.9%. Compared with the active control group, the median body weight and body mass index of the intervention group significantly decreased at 3 months (-0.4 [-2.0, 0.6] vs. -1.1 [-2.7, -0.5] kg, P=0.026; -0.1 [-0.6, 0.3] vs. -0.4 [-0.8, -0.2] kg, P=0.022, respectively). The intervention increased the percentage of participants taking ≥8,000 steps, vegetable intake before rice, slow eating speed, and relaxation. Personality traits were associated with the degree of weight loss in the intervention group.

Conclusions:

The SHG-specific KENPO-app was feasible and induced modest but significant weight loss in adults with obesity. Clinical Trial: Registration No. of the study/trial: Trial registration number: University hospital Medical Information Network (UMIN) Center: UMIN000046263).


 Citation

Please cite as:

Sakane N, Suganuma A, Domichi M, Sukino S, Abe K, Fujisaki A, Kanazawa A, Sugimoto M

The Effect of a mHealth App (KENPO-app) for Specific Health Guidance on Weight Changes in Adults With Obesity and Hypertension: Pilot Randomized Controlled Trial

JMIR Mhealth Uhealth 2023;11:e43236

DOI: 10.2196/43236

PMID: 37043287

PMCID: 10134028

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.